Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. YDES
YDES logo

YDES Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.879
Open
2.700
VWAP
2.62
Vol
31.65K
Mkt Cap
178.49M
Low
2.450
Amount
82.82K
EV/EBITDA(TTM)
--
Total Shares
70.83M
EV
182.36M
EV/OCF(TTM)
--
P/S(TTM)
314.91
YD Bio Limited is a biopharmaceutical company. The Company is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. It is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. It is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. It is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
Show More

Events Timeline

(ET)
2026-04-07
16:00:00
YD Bio Ltd Trading Halted Due to Volatility
select
2026-03-23 (ET)
2026-03-23
09:50:00
YD Bio Ltd Trading Halted Due to Volatility
select
2026-03-17 (ET)
2026-03-17
08:30:00
YD Bio Aims for Conditional Clinical Milestone in Taiwan by 2027 for Glioblastoma Therapy
select
2026-02-25 (ET)
2026-02-25
08:20:00
YD Bio Enters Strategic Alliance Agreement with YC Biotech
select
2026-01-29 (ET)
2026-01-29
08:50:00
YD Bio Signs LOI to Acquire SSMC
select
2026-01-06 (ET)
2026-01-06
09:10:00
YD Bio Enters MOU to Merge with EG BioMed
select
2026-01-05 (ET)
2026-01-05
09:20:00
YD Bio Completes Key Milestones, Plans Three Acquisitions in 2026
select
2025-12-16 (ET)
2025-12-16
09:10:00
YD Bio Initiates New Facility Plans in California
select

News

Newsfilter
9.5
04-30Newsfilter
YD Bio Reports Significant Growth in 2025 Financial Results
  • Significant Revenue Growth: YD Bio reported net revenue of $596,817 for 2025, a 17% increase driven primarily by higher pharmaceutical sales volumes and successful new product launches, indicating the company's competitive position and growth potential in the market.
  • Increased R&D Investment: The company raised its R&D expenditures by approximately $1.1 million to secure essential patents and technological know-how, a strategic investment designed to support growth across multiple regulated healthcare segments.
  • Improved Cash Flow Position: As of December 31, 2025, YD Bio's cash and cash equivalents reached $6 million, a significant increase from $3.1 million in 2024, enhancing the company's financial flexibility for operations in 2026.
  • Strategic M&A Plans: YD Bio aims to integrate DNA methylation-driven AI platforms into its oncology programs through a merger with EG BioMed, demonstrating proactive efforts in building a diversified healthcare platform.
seekingalpha
9.5
04-30seekingalpha
YD Bio Limited Reports FY Financial Results
  • Financial Overview: YD Bio Limited reported its FY financial results with a GAAP EPS of -$0.12, indicating challenges in profitability that may affect investor confidence.
  • Revenue Growth: The company achieved revenue of $0.6 million, reflecting a 17.6% year-over-year increase, suggesting a potential recovery in market demand that could lay the groundwork for future growth.
  • Market Reaction: Given the negative EPS, the market may adopt a cautious stance regarding the company's future profitability, prompting investors to closely monitor subsequent strategic adjustments and market performance.
  • Future Outlook: Despite the current financial underperformance, the revenue growth could provide opportunities for the company to improve its profitability, necessitating effective strategies from management to enhance competitive positioning in the market.
NASDAQ.COM
2.0
04-16NASDAQ.COM
YD Bio Shares Enter Oversold Territory
  • Oversold Signal: YD Bio Limited (Ticker: YDES) entered oversold territory on Thursday with an RSI of 29.9, hitting a low of $5.195 per share, indicating that recent heavy selling may be exhausting.
  • Market Comparison: In contrast to the S&P 500 ETF (SPY) with an RSI of 68.3, YD Bio's low RSI could attract bullish investors looking for buying opportunities, suggesting a potential shift in market sentiment.
  • Price Fluctuation: Over the past 52 weeks, YD Bio's stock has seen a low of $5.12 and a high of $25, with the latest trade at $5.20, indicating volatility near the lower end of its range.
  • Investor Interest: As YDES enters oversold territory, investors may also look at 9 other oversold stocks for potential investment opportunities, reflecting market interest in undervalued stocks.
NASDAQ.COM
2.0
01-06NASDAQ.COM
YD Bio Completes Key Milestones, Enters 2026 with New Opportunities
  • Scientific Progress: YD Bio has completed key Chemistry, Manufacturing, and Controls (CMC) activities, laying the groundwork for its stem cell and exosome programs, which is expected to accelerate the transition from platform validation to asset-level clinical and commercial development.
  • Regulatory Advancement: The company filed Drug Master Files (DMFs) with the U.S. FDA for its stem cell and exosome platforms, creating a reusable regulatory framework for future IND submissions, despite no products being approved yet.
  • Market Performance: YD Bio commenced trading on the Nasdaq under the ticker symbol YDES on August 29, 2025, with the stock currently priced at $13.39, reflecting a 5.06% increase, indicating market confidence in its future prospects.
  • Future Outlook: The company anticipates entering a
Benzinga
2.0
2025-11-28Benzinga
Major Stocks Including Micron, Endeavour Silver, First Majestic Silver, and Applied Digital Experience Gains on Friday
  • U.S. Stock Market Performance: U.S. stocks rose on Friday, with the Dow Jones gaining approximately 300 points, driven by positive earnings reports, particularly from Dell, which boosted investor sentiment in the tech sector.

  • Micron Technology Surge: Shares of Micron Technology increased by 2.5% to $235.92, as investors interpreted Dell's strong earnings as a sign of broader strength in the technology market.

  • Notable Stock Gains: Several companies saw significant stock price increases, including DeFi Technologies (up 20.5%), YD Bio Ltd (up 13.7%), and Savara Inc (up 12.3%), reflecting positive developments in their respective sectors.

  • Precious Metals and Crypto Stocks Rise: Stocks related to precious metals and cryptocurrencies also experienced gains, with First Majestic Silver Corp and Intel Corporation rising notably, as gold and silver prices increased and Bitcoin surpassed $90,000.

Benzinga
2.0
2025-11-26Benzinga
Major Stocks on the Rise Wednesday: Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness, and More
  • U.S. Stock Market Performance: U.S. stocks rose on Wednesday, with the Dow Jones gaining over 300 points, driven by strong earnings reports from several companies.

  • Urban Outfitters Earnings Report: Urban Outfitters Inc. reported third-quarter earnings of $1.28 per share and revenue of $1.53 billion, both exceeding analyst expectations, leading to a 10.1% increase in its stock price.

  • Notable Stock Gains: Other companies like Falcon’s Beyond Global Inc. and Ironwood Pharmaceuticals saw significant stock price increases of 26% and 18.7%, respectively, following positive news and earnings reports.

  • Market Reactions to Company Announcements: Stocks such as Robinhood Markets and Petco Health and Wellness surged after announcing new initiatives and better-than-expected earnings, reflecting positive investor sentiment.

Valuation Metrics

The current forward P/E ratio for YD Bio Ltd (YDES.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess YD Bio Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding YDES

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is YD Bio Ltd (YDES) stock price today?

The current price of YDES is 2.52 USD — it has decreased -5.26

What is YD Bio Ltd (YDES)'s business?

YD Bio Limited is a biopharmaceutical company. The Company is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. It is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. It is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. It is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.

What is the price predicton of YDES Stock?

Wall Street analysts forecast YDES stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for YDES is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is YD Bio Ltd (YDES)'s revenue for the last quarter?

YD Bio Ltd revenue for the last quarter amounts to 160.24K USD, increased 39.42

What is YD Bio Ltd (YDES)'s earnings per share (EPS) for the last quarter?

YD Bio Ltd. EPS for the last quarter amounts to -0.00 USD, decreased

How many employees does YD Bio Ltd (YDES). have?

YD Bio Ltd (YDES) has 13 emplpoyees as of June 19 2026.

What is YD Bio Ltd (YDES) market cap?

Today YDES has the market capitalization of 178.49M USD.